TG Therapeutics and Twist Bioscience reported earnings below analyst estimates due to higher-than-expected operating expenses.
TG Therapeutics reported a Q2 loss of 5 cents per share, missing the Street’s forecast of a 31-cent gain. The miss stemmed from analysts underestimating operating expenses, which weighed on profitability. Shares fell in response to the shortfall, reflecting investor disappointment.
Twist Bioscience also posted weaker-than-expected earnings, though specifics were not detailed. Both companies had been closely watched ahead of earnings, with prior consensus estimates anticipating stronger performance. The divergence highlights cost pressures in the biotech sector.
Markets reacted negatively to the reports, with both stocks declining in early trading. The results contrast with broader sector trends, where some firms have managed to meet or exceed expectations.